BRPI0410343A - truncated forms of human dbf4, complex with their interaction pairs, and methods for identifying their inhibitors - Google Patents

truncated forms of human dbf4, complex with their interaction pairs, and methods for identifying their inhibitors

Info

Publication number
BRPI0410343A
BRPI0410343A BRPI0410343-2A BRPI0410343A BRPI0410343A BR PI0410343 A BRPI0410343 A BR PI0410343A BR PI0410343 A BRPI0410343 A BR PI0410343A BR PI0410343 A BRPI0410343 A BR PI0410343A
Authority
BR
Brazil
Prior art keywords
human
complex
dbf4
truncated forms
inhibitors
Prior art date
Application number
BRPI0410343-2A
Other languages
Portuguese (pt)
Inventor
Barbara Valsasina
Cinzia Cristiani
Stefan Knapp
Sandrine Thieffine
Rita Perego
Maria Beatrice Saccardo
Henryk Kalisz
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BRPI0410343A publication Critical patent/BRPI0410343A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"FORMAS TRUNCADAS DE Dbf4 HUMANA, COMPLEXOS COM SEUS PARES DE INTERAçãO E MéTODOS PARA IDENTIFICAçãO DE SEUS INIBIDORES". A presente invenção refere-se em geral ao esboço, expressão e purificação de formas truncadas da proteína dfb4 humana, opcionalmente em complexo com pares de interação com dbf4, tal como edc7 humana, e ao seu uso no encontro, identificação e caracterização de inibidores dos componentes do complexo, ou quando associadas ou quando presentes como proteínas não-complexadas in situ ou in vitro. Mais especificamente, a presente invenção refere-se à utilização de formas truncadas específicas de dbf4 humana para a produção de um heterodímero ativo, não-agregado, monodisperso, de dbf4 humana complexada para cdc7 humana, ou outros agentes de interação de proteína."Truncated forms of Dbf4 HUMAN, COMPLEX WITH ITS INTERACTION COUPLES AND METHODS FOR IDENTIFYING YOUR INHIBITORS". The present invention relates generally to the sketching, expression and purification of truncated forms of human dfb4 protein, optionally in complex with dbf4 interaction pairs such as human edc7, and its use in the discovery, identification and characterization of human dfb4 inhibitors. components of the complex, or when associated or when present as non-complexed proteins in situ or in vitro. More specifically, the present invention relates to the use of specific truncated forms of human dbf4 for the production of an active, non-aggregated, monodispersed, human cdc7 complexed human dbf4 heterodimer, or other protein interaction agents.

BRPI0410343-2A 2003-05-05 2004-04-20 truncated forms of human dbf4, complex with their interaction pairs, and methods for identifying their inhibitors BRPI0410343A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46795603P 2003-05-05 2003-05-05
PCT/EP2004/050568 WO2004099243A2 (en) 2003-05-05 2004-04-20 Truncated forms of human dbf4, complexes with their interacting partners and methods for identification of inhibitors thereof

Publications (1)

Publication Number Publication Date
BRPI0410343A true BRPI0410343A (en) 2006-05-30

Family

ID=33435149

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410343-2A BRPI0410343A (en) 2003-05-05 2004-04-20 truncated forms of human dbf4, complex with their interaction pairs, and methods for identifying their inhibitors

Country Status (4)

Country Link
EP (1) EP1622934A2 (en)
BR (1) BRPI0410343A (en)
CA (1) CA2524528A1 (en)
WO (1) WO2004099243A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TWI796642B (en) 2015-08-28 2023-03-21 德商英麥提克生物技術股份有限公司 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US10159726B2 (en) 2015-08-28 2018-12-25 Immatics Biotechnologies Gmbh Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076623A1 (en) * 2002-03-12 2003-09-18 Japan Science And Technology Agency Cdc7-ASK KINASE COMPLEX, SUBSTRATE OF THE KINASE COMPLEX, ANTIBODY SPECIFIC TO THE SUBSTRATE, AND METHOD OF SCREENING COMPOUND CAPABLE OF INHIBITING Cdc7-ASK KINASE USING THE SAME

Also Published As

Publication number Publication date
CA2524528A1 (en) 2004-11-18
WO2004099243A8 (en) 2005-03-03
EP1622934A2 (en) 2006-02-08
WO2004099243A2 (en) 2004-11-18
WO2004099243A3 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
DE60206028D1 (en) OXAZOLYLPYRAZOLE DERIVATIVES AS KINASE INHIBITORS
DE60313597D1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS WITH PROANTHOCYANIDINES, GLYCYRRHETINIC ACID AND TELEMINE TESTS FOR THE TREATMENT OF DERMATITIS
ECSP088350A (en) PIRAZOLOPIRIMIDINAS AS INHIBITORS OF PROTEIN KINASES
DE602005026031D1 (en) CRYSTALLINE FORMS OF (-) - (1R, 2R) -3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL) -PHENOLHYDROCHLORIDE FOR USE AS AN ACTIVE IN PHARMACEUTICAL PREPARATIONS
BR0007527A (en) Phenylphenanthridines with IV-dependent inhibitory activity
BR0316234A (en) Hydroxyindols, their use as phosphodiesterase 4 inhibitors and processes for their preparation
DE602004024037D1 (en) SUBSTITUTED HETEROCYCLES
BRPI0408782A (en) cyclic protein tyrosine kinase inhibitors
ATE420883T1 (en) PYRROLOPYRIMIDINES USED AS PROTEIN KINASE INHIBITORS
BRPI0414000B8 (en) Solid oral extended-release pharmaceutical composition containing tacrolimus in the form of a solid dispersion, dosage form, and use of the pharmaceutical composition
TW200640487A (en) Combination of XOLAIR with immunosuppressive agent
ATE433973T1 (en) AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
BRPI0407583A (en) clearly and stable ophthalmic solution
DK1327143T3 (en) Crystal structure of BACE and its use
ATE350377T1 (en) SUBSTITUTED 3-PYRROLIDINE INDOLE DERIVATIVES
BR0314797A (en) Pyrimidineamide derivatives and their use
CY1108540T1 (en) IDENTIFICATION OF THERAPEUTIC UNIONS
ATE496892T1 (en) TETRAHYDROISOCINOLINE COMPOUNDS FOR THE TREATMENT OF CNS DISEASES
DK1228097T3 (en) Antimicrobial activity of the first cationic human lactoferrin cluster
GT200200279A (en) ANTIBODY INHIBITING THE ACTIVITY OF THE PRECURSOR CELL FACTOR AND ITS USE FOR THE TREATMENT OF ASTHMA
BRPI0410343A (en) truncated forms of human dbf4, complex with their interaction pairs, and methods for identifying their inhibitors
BRPI0616535B8 (en) use of lipidated tissue factor (tf) or a functional fragment thereof, product, use of a product, complex (tf::fxa), use of a complex, tf::ncis complex, tf::fxa:ncis complex, pharmaceutical composition and use of non-lipidated tf or a functional fragment thereof
DE50213507D1 (en) METHOD AND MEANS FOR INFLUENCING INTERCELLULAR COMMUNICATION AND INTERCELLULAR ORGANIC TRANSPORT
ATE361068T1 (en) ACTIVE SUBSTANCE FOR REMOVAL OF AN UNDESIRABLE PROTEIN POPULATION FROM THE PLASMA
HUP0204208A2 (en) Antipruritic agents for external use

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]